Sinovac Biotech

Sinovac Biotech Ltd. (Chinese: 北京科兴生物制品有限公司, NASDAQ: SVA) is a biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. The company is based in Beijing, China.

Sinovac Biotech
Founded1999 (1999)
Headquarters
Beijing
,
China
Websitehttp://www.sinovac.com/

Sinovac's commercialized vaccines include Healive (hepatitis A), Bilive (combined hepatitis A and B), Anflu (influenza), Panflu (H5N1) and PANFLU.1 (H1N1). Sinovac is currently developing Universal Pandemic Influenza vaccine and Japanese encephalitis vaccine.[1]

Sinovac is developing vaccines for enterovirus 71, universal pandemic influenza, Japanese encephalitis, and human rabies. Its wholly owned subsidiary, Tangshan Yian, is conducting field trials for independently developed inactivated animal rabies vaccines.

In mid-April 2020, China approved a clinical trial for a candidate COVID-19 vaccine developed by Sinovac.[2]

See also

References
  1. Google Finance, url=https://www.google.com/finance?q=Sinovac
  2. Zhang Zhihao (15 April 2020). "Three COVID-19 vaccines approved for clinical trials". China Daily. Retrieved 23 April 2020.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.